Trial
NCT03642132
Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Ovarian Cancer
Intervention
Chemotherapy + avelumab followed by avelumab + talazoparib
Why stopped
Phase 3 B9991010 study was stopped due to futility of efficacy at interim analysis on 21Dec2018, and approvals of PARP inhibitors in front-line maintenance setting, Pfizer decided stopping enrollment in the B9991030 study on 19Mar2019.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-06